[ed. From the Ask Anything series on Andrew Sullivan's blog, The Dish. Additional videos are listed below.]
In today’s video from drug researcher Rick Doblin, he surveys some little known but promising psychedelic treatments, including one that might dramatically improve end of life care.
• What is the biggest myth about psychedelic drugs?
• How important is some kind of guidance when it comes to having a beneficial psychedelic experience?
• What has been the most encouraging finding from your research on psychedelics?
• What will it take for national policy towards psychedelics to change?
• Are there any promising psychedelics that are not widely known about yet?
Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard’s Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master’s thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences.
His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and three children.by Andrew Sullivan, The Dish | Read more:
